Researchers at Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have identified cyclohexane compounds acting as dopamine and/or 5-HT1A receptor ligands reported to be useful for the treatment of depression, schizophrenia, phobia, obsessive-compulsive disorder, cognitive disorders and bipolar disorder, among others.